Permanent Supportive Housing With Housing First: Findings From a Community Guide Systematic Economic Review.


Journal

American journal of preventive medicine
ISSN: 1873-2607
Titre abrégé: Am J Prev Med
Pays: Netherlands
ID NLM: 8704773

Informations de publication

Date de publication:
03 2022
Historique:
received: 19 05 2021
revised: 03 08 2021
accepted: 16 08 2021
pubmed: 15 11 2021
medline: 1 4 2022
entrez: 14 11 2021
Statut: ppublish

Résumé

The annual economic burden of chronic homelessness in the U.S. is estimated to be as high as $3.4 billion. The Permanent Supportive Housing with Housing First (Housing First) program, implemented to address the problem, has been shown to be effective. This paper examines the economic cost and benefit of Housing First Programs. The search of peer-reviewed and gray literature from inception of databases through November 2019 yielded 20 evaluation studies of Housing First Programs, 17 from the U.S. and 3 from Canada. All analyses were conducted from March 2019 through July 2020. Monetary values are reported in 2019 U.S. dollars. Evidence from studies conducted in the U.S. was separated from those conducted in Canada. The median intervention cost per person per year for U.S. studies was $16,479, and for all studies, including those from Canada, it was $16,336. The median total benefit for the U.S. studies was $18,247 per person per year, and it was $17,751 for all studies, including those from Canada. The benefit-to-cost ratio for U.S. studies was 1.80:1, and for all studies, including those from Canada, it was 1.06:1. The evidence from this review shows that economic benefits exceed the cost of Housing First Programs in the U.S. There were too few studies to determine cost-benefit in the Canadian context.

Identifiants

pubmed: 34774389
pii: S0749-3797(21)00482-7
doi: 10.1016/j.amepre.2021.08.009
pmc: PMC8863642
mid: NIHMS1768403
pii:
doi:

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S. Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e188-e201

Subventions

Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Références

PLoS One. 2016 May 10;11(5):e0155065
pubmed: 27163478
Inquiry. 2010 Summer;47(2):124-34
pubmed: 20812461
Demography. 2015 Jun;52(3):729-49
pubmed: 26047935
Value Health. 2004 Sep-Oct;7(5):518-28
pubmed: 15367247
BMC Health Serv Res. 2018 Jan 10;18(1):15
pubmed: 29316920
Psychiatr Serv. 2010 Nov;61(11):1093-8
pubmed: 21041347
Health Serv Res. 2013 Jun;48(3):992-1017
pubmed: 23134588
J Econ Perspect. 2011 Spring;25(2):3-25
pubmed: 21595323
J Public Health Manag Pract. 2020 Sep/Oct;26(5):404-411
pubmed: 32732712
Am J Public Health. 2013 Dec;103 Suppl 2:S262-8
pubmed: 24148064
Psychiatr Serv. 1998 Jul;49(7):946-50
pubmed: 9661231
Psychiatr Serv. 2009 Apr;60(4):445-50
pubmed: 19339318
Psychiatr Serv. 2016 Jun 1;67(6):615-21
pubmed: 26828399
Am J Public Health. 2013 Dec;103 Suppl 2:S282-8
pubmed: 24148043
J Subst Abuse Treat. 2014 Apr;46(4):491-7
pubmed: 24462220
CMAJ Open. 2017 Jul 18;5(3):E576-E585
pubmed: 28724726
Epidemiol Rev. 2015;37:177-95
pubmed: 25595171
JAMA. 2009 Apr 1;301(13):1349-57
pubmed: 19336710
Psychiatr Serv. 2020 Oct 1;71(10):1020-1030
pubmed: 32838679
Arch Gen Psychiatry. 2003 Sep;60(9):940-51
pubmed: 12963676
Psychiatr Serv. 2014 Sep 1;65(9):1120-5
pubmed: 24829104
BMJ Open. 2019 Apr 24;9(4):e025192
pubmed: 31023754
Arch Gen Psychiatry. 2010 Jun;67(6):645-52
pubmed: 20530014
Am J Public Health. 2013 Dec;103 Suppl 2:S275-81
pubmed: 24148049
JAMA Netw Open. 2019 Aug 2;2(8):e199782
pubmed: 31433483
Health Serv Res. 2012 Feb;47(1 Pt 2):523-43
pubmed: 22098257
Am J Public Health. 2013 Feb;103(2):316-21
pubmed: 23237150
Public Health Rev. 2001;29(1):13-33
pubmed: 11780714
Lancet Public Health. 2020 Jun;5(6):e342-e360
pubmed: 32504587
AIDS Behav. 2013 Jun;17(5):1626-31
pubmed: 22588529
BMC Public Health. 2009 Jan 07;9:3
pubmed: 19128448
Am J Public Health. 2005 Oct;95(10):1753-9
pubmed: 16131638
J Public Health (Oxf). 2018 Mar 1;40(1):65-74
pubmed: 28335013
Am J Public Health. 2004 Apr;94(4):651-6
pubmed: 15054020
Lancet. 2014 Oct 25;384(9953):1529-40
pubmed: 25390578

Auteurs

Verughese Jacob (V)

From the Community Guide Office, Office of the Associate Director for Policy and Strategy, Centers for Disease Control and Prevention, Atlanta, Georgia. Electronic address: hir0@cdc.gov.

Sajal K Chattopadhyay (SK)

From the Community Guide Office, Office of the Associate Director for Policy and Strategy, Centers for Disease Control and Prevention, Atlanta, Georgia.

Sharon Attipoe-Dorcoo (S)

From the Community Guide Office, Office of the Associate Director for Policy and Strategy, Centers for Disease Control and Prevention, Atlanta, Georgia.

Yinan Peng (Y)

From the Community Guide Office, Office of the Associate Director for Policy and Strategy, Centers for Disease Control and Prevention, Atlanta, Georgia.

Robert A Hahn (RA)

From the Community Guide Office, Office of the Associate Director for Policy and Strategy, Centers for Disease Control and Prevention, Atlanta, Georgia.

Ramona Finnie (R)

From the Community Guide Office, Office of the Associate Director for Policy and Strategy, Centers for Disease Control and Prevention, Atlanta, Georgia.

Jamaicia Cobb (J)

From the Community Guide Office, Office of the Associate Director for Policy and Strategy, Centers for Disease Control and Prevention, Atlanta, Georgia.

Alison E Cuellar (AE)

Department of Health Administration and Policy, College of Health and Human Services, George Mason University, Fairfax, Virginia.

Karen M Emmons (KM)

Department of Social and Behavioral Sciences, School of Public Health, Harvard T.H. Chan University, Cambridge, Massachusetts.

Patrick L Remington (PL)

Department of Population Health Sciences, UW-Madison School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH